United States Patent 6,004,996: Orlistat Pellet Formulation Scope, Expiration, and Patent Landscape

U.S. Patent No. 6,004,996 protects a specific multiparticulate formulation of tetrahydrolipstatin, the active ingredient now known as orlistat. Its core requirement is a population of small pellets, generally 0.25 to 2 mm in diameter, containing approximately 50% by weight active ingredient together with polyvinylpyrrolidone, microcrystalline cellulose, and a pharmaceutically acceptable excipient. The patent does not claim orlistat as a molecule, the therapeutic use of orlistat generally, or every oral dosage form.

The patent’s commercial relevance was directed primarily to Roche’s Xenical 120 mg capsules. The patent term has expired, eliminating current U.S. patent exclusivity from this patent, although formulation, manufacturing, regulatory, and product-specific barriers may still affect generic competition.

What does U.S. Patent 6,004,996 cover?

U.S. Patent 6,004,996 covers an oral pharmaceutical composition made from relatively uniform orlistat-containing pellets. The principal independent claim requires all of the following:

Claim element	Requirement
Active ingredient	Approximately 50% by weight tetrahydrolipstatin, or orlistat
Physical form	A plurality of pellets
Pellet diameter	About 0.25 mm to about 2 mm
Size distribution	At most only a trace amount of pellets outside that range
Binder or excipient	Polyvinylpyrrolidone
Filler or structural excipient	Microcrystalline cellulose
Additional excipient	At least one pharmaceutically acceptable excipient

Claim 1 is an open-ended composition claim because it uses the term “comprising.” A product containing the listed components may still fall within the claim if it contains additional ingredients, provided the required pellet and composition limitations are met.

The claim is narrower than a claim to an orlistat capsule generally. A formulation containing orlistat in a tablet, liquid, amorphous dispersion, conventional powder, or pellet population outside the claimed size profile would not satisfy every limitation of claim 1.

What are the claims of U.S. Patent 6,004,996?

The 15 claims form a hierarchy covering pellet size, excipient selection, composition percentages, and unit dosage forms.

Independent composition claim

Claim 1 is the key composition claim. It requires pellets with a diameter of approximately 0.25 to 2 mm and only a trace amount outside that range. Each pellet must contain approximately 50% orlistat, polyvinylpyrrolidone, microcrystalline cellulose, and at least one acceptable excipient.

The phrase “each pellet comprising” is significant. The required ingredients must be present in the pellets themselves, rather than merely elsewhere in a capsule or dosage unit.

Narrower pellet-size claim

Claim 2 narrows the pellet diameter to approximately 0.5 to 1.5 mm. A formulation meeting claim 2 would also need to meet the other limitations inherited from claim 1.

Polyvinylpyrrolidone threshold

Claim 3 requires at least 5% by weight polyvinylpyrrolidone. This limitation captures the disclosed commercial-style formulation more closely than claim 1, which does not state a numerical PVP minimum.

Excipient subclasses

Claims 4 through 10 divide the additional excipient into functional categories:

Claim 4: surfactant, diluent, or disintegrant.
Claim 5: surfactant.
Claim 6: sodium lauryl sulfate or sodium dioctylsulfosuccinate.
Claim 7: diluent.
Claim 8: sucrose or corn starch.
Claim 9: disintegrant.
Claim 10: sodium starch glycolate, cross-linked polyvinylpyrrolidone, croscarmellose sodium, or hydroxypropyl cellulose.

These claims create alternative infringement routes. A formulation does not need to use sodium lauryl sulfate if it uses another qualifying excipient category and satisfies the broader inherited limitations.

Specific composition claim

Claim 11 recites the following approximate composition:

Component	Approximate percentage
Tetrahydrolipstatin	50%
Microcrystalline cellulose	39%
Sodium starch glycolate	3%
Sodium lauryl sulfate	3%
Polyvinylpyrrolidone	5%
Talc	0.1%

The listed percentages total approximately 100.1%, which is consistent with the use of “about.” Claim 11 remains dependent on claim 1 and therefore retains the pellet-size and per-pellet requirements.

Unit dosage claims

Claims 12 and 13 cover the claimed compositions in unit dosage form. Claims 14 and 15 recite an approximately 120 mg orlistat unit with the following quantities:

Component	Approximate amount
Tetrahydrolipstatin	120 mg
Microcrystalline cellulose	93.6 mg
Sodium starch glycolate	7.2 mg
Sodium lauryl sulfate	7.2 mg
Polyvinylpyrrolidone	12 mg
Talc	0.24 mg

The total is approximately 240.24 mg. Claim 15 limits that formulation to a unit dosage form.

How strong is the patent estate for U.S. Patent 6,004,996?

The patent was technically meaningful but commercially narrow. Its strength came from the combination of composition, pellet engineering, and dosage-unit limitations. Its weakness was that an accused product would need to satisfy a substantial number of structural and quantitative limitations.

Strengths

The patent has several features that could support an infringement case:

The claim reaches the pellet population, not merely the final capsule.
The size-distribution limitation addresses manufacturing control and may distinguish ordinary pellet formulations.
The claim combines orlistat loading with PVP and microcrystalline cellulose.
Claims 11, 14, and 15 closely track a defined commercial composition.
The dependent claims identify common excipients used in oral solid dosage manufacturing.

Vulnerabilities

The principal vulnerabilities are claim construction and proof:

“About 50%” requires a legally meaningful tolerance range.
“At most only a trace amount” is not expressed as a numerical percentage.
Pellet diameter can vary depending on sampling method, measurement technique, and manufacturing batch.
The claims require the ingredients in each pellet, which may be difficult to establish from finished-product testing.
A generic manufacturer may design around the claim by changing pellet size, active loading, binder, filler, or excipient architecture.
Claims 14 and 15 are vulnerable to noninfringement arguments based on quantitative deviations from the listed unit composition.

Because the patent has expired, these issues no longer create prospective U.S. exclusivity. They remain relevant to historical litigation and to freedom-to-operate assessments concerning related foreign patents or unexpired continuation patents.

When did U.S. Patent 6,004,996 expire?

U.S. Patent 6,004,996 was granted on December 21, 1999. Its ordinary 20-year patent term ran from the applicable U.S. nonprovisional filing date, resulting in expiration in June 2017. Public patent databases and Orange Book records identify June 2017 as the relevant end of the patent term.[1,2]

Event	Date or status
U.S. patent filing and priority chain	1990s
Patent grant	December 21, 1999
Listed product association	Roche Xenical, orlistat 120 mg
Patent term	Expired in June 2017
Current enforceability	No prospective U.S. patent exclusivity from this patent

Patent term adjustment, patent term extension, pediatric exclusivity, or terminal-disclaimer information should be checked against the official Patent Center record when calculating a historical launch date. The expiration of the patent itself does not establish when each generic manufacturer entered the market.

What is the Orange Book status of U.S. Patent 6,004,996?

U.S. Patent 6,004,996 was associated with Xenical, Roche’s prescription orlistat product. The Orange Book identifies patents submitted by an NDA holder as covering the listed drug or an approved method of using it.[2]

The patent is a formulation patent rather than a basic active-ingredient patent. Its listing could require an ANDA applicant to address the patent through one of the statutory certification pathways, including a Paragraph IV certification asserting that the patent was invalid, unenforceable, or would not be infringed.

The listing did not mean that every generic orlistat product infringed the patent. It meant that the applicant had to address the patent if the proposed product and the relevant Orange Book listing brought it within the ANDA certification framework.

Which companies challenged the Xenical patent estate?

The principal commercial challengers to Xenical were generic-drug companies pursuing ANDA approval for orlistat capsules. Public litigation records should be reviewed case by case because ANDA disputes often involve multiple Roche patents, not only U.S. Patent 6,004,996.

The relevant competitive group included companies seeking approval for 120 mg orlistat capsules, including large generic manufacturers and applicants associated with the post-expiration market. The major legal issue was whether the proposed products reproduced Roche’s pellet composition and size distribution, rather than whether they contained orlistat alone.

The legal consequences of a Paragraph IV filing generally included:

Notice to the patent owner and NDA holder.
A possible 30-month stay of FDA approval under the Hatch-Waxman framework.
Patent litigation in federal district court.
Potential settlement, license, or launch agreement.
FDA approval after patent expiry, litigation resolution, or expiration of the statutory stay.

The patent’s expiration in 2017 removed the forward-looking barrier created by this specific formulation patent. Any settlement terms governing earlier entry would remain relevant to historical market timing but would not revive the expired patent.

Did U.S. Patent 6,004,996 create generic launch risk?

Yes. Before expiry, the patent created a formulation-specific risk for a generic manufacturer whose product used:

Orlistat loading near 50% by weight.
Microcrystalline cellulose and PVP in the same pellets.
Pellet diameters within approximately 0.25 to 2 mm.
Sodium lauryl sulfate, sodium starch glycolate, or a listed alternative excipient.
A 120 mg unit dosage with quantities close to claim 14.

A generic could reduce risk through a design-around strategy. Potential design variables included:

Design variable	Possible noninfringing direction
Pellet diameter	Use a materially different size distribution
Active loading	Use a materially different orlistat percentage
Binder	Replace PVP with another binder
Filler	Replace microcrystalline cellulose
Surfactant	Use a different formulation system
Dosage architecture	Use a non-pellet or differently structured multiparticulate system
Manufacturing process	Avoid producing the claimed per-pellet composition

These strategies would require technical validation. Changing one ingredient may create dissolution, stability, manufacturability, or bioequivalence problems.

What manufacturing and intellectual-property barriers did the patent create?

The patent was directed to a formulation process outcome: uniformly sized pellets with high orlistat loading and defined excipient architecture. That creates several manufacturing barriers:

Pellet size must be controlled within a narrow distribution.
Orlistat must be incorporated consistently into each pellet.
PVP and microcrystalline cellulose must support pellet formation without compromising dissolution.
The excipient system must produce an acceptable release profile.
Finished-product testing must verify dosage uniformity and stability.
The manufacturer must scale the pelletization process without creating excessive out-of-range particles.

The patent did not, based on the supplied claims, claim a particular pelletization apparatus or a broad manufacturing process. Its central enforcement theory would therefore focus on the composition of the resulting pellets.

How does this patent compare with other orlistat patents?

Patent category	Subject matter	Commercial significance
Active-ingredient or therapeutic patents	Orlistat or tetrahydrolipstatin and its use	Broader in concept but expired earlier or separately
U.S. Patent 6,004,996	Orlistat pellets with defined size, loading, and excipients	Formulation-specific protection for Xenical-type dosage units
Method-of-use patents	Administration of orlistat for obesity or weight management	May affect labeling and skinny-label strategy
Manufacturing patents	Pelletization, particle control, coating, or process conditions	May create separate design-around barriers
Foreign counterparts	National equivalents in Europe and other markets	Expiration and validity vary by jurisdiction

The patent should therefore be analyzed as one layer of the Xenical patent estate, not as the complete exclusivity position for orlistat.

Was there biosimilar risk for this patent?

No. Orlistat is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an abbreviated new drug application, not a biosimilar application under the Public Health Service Act.

FDA competition involved generic orlistat products evaluated for pharmaceutical equivalence and bioequivalence. The key regulatory issues were capsule strength, formulation performance, labeling, manufacturing controls, and bioequivalence rather than biosimilarity.[3,4]

What was the licensing and commercial landscape?

Roche commercialized Xenical as a prescription 120 mg orlistat product. GlaxoSmithKline commercialized Alli, a lower-dose over-the-counter orlistat product, under a commercial relationship with Roche. The prescription and OTC products had different regulatory positioning and dosage strengths, although both relied on the same active ingredient.

The patent’s revenue exposure was concentrated in the Xenical franchise before broad generic competition. The formulation patent could support brand pricing and delay direct generic substitution during its enforceable term. After expiry, commercial protection depended more heavily on brand recognition, regulatory status, manufacturing scale, distribution, and consumer demand.

What is the current legal and commercial status?

U.S. Patent 6,004,996 is expired. It does not provide a current U.S. patent basis for blocking the manufacture, approval, or sale of a conforming generic orlistat pellet formulation.

Current diligence should distinguish:

Expired U.S. Patent 6,004,996.
Other U.S. patents that may have covered orlistat, methods of use, or manufacturing.
Foreign counterparts with different expiration histories.
FDA exclusivity, which is separate from patent rights.
Product-specific formulation patents filed after the original Xenical estate.
Trade-secret manufacturing information that is not disclosed in the patent.

Key Takeaways

U.S. Patent 6,004,996 is a formulation patent for orlistat pellets.
Claim 1 requires approximately 50% orlistat, PVP, microcrystalline cellulose, an additional excipient, and a tightly controlled pellet-size population.
Claims 11, 14, and 15 target specific Xenical-type compositions and a 120 mg unit dosage form.
The patent does not broadly cover all orlistat products.
The most important infringement variables are pellet size, per-pellet composition, active loading, and excipient selection.
The patent expired in June 2017.
Orlistat competition proceeds through the generic-drug pathway, not the biosimilar pathway.
Current market barriers are more likely to arise from other patents, manufacturing capability, regulatory compliance, and commercial scale than from U.S. Patent 6,004,996.

FAQs

Does U.S. Patent 6,004,996 cover Alli?

Not automatically. Alli is an OTC orlistat product at a lower dose and would need to be evaluated against every limitation of the asserted claim, including pellet size, per-pellet composition, excipients, and active loading. The patent’s expiration also removes any current U.S. blocking right.

Can a generic use sodium lauryl sulfate without infringing?

Yes, in principle. Sodium lauryl sulfate is specifically listed in dependent claim 6, but use of that excipient alone does not determine infringement. The product would still need to be evaluated against the pellet-size, active-loading, PVP, microcrystalline-cellulose, and other inherited limitations.

Is a 120 mg orlistat capsule automatically covered by claim 14?

No. Claim 14 requires the specified approximate quantities and remains dependent on claim 1. A 120 mg capsule using a different pellet structure or materially different excipient composition may fall outside the claim.

Does patent expiry eliminate all orlistat launch restrictions?

No. Expiry eliminates the rights provided by this patent. Other patents, regulatory exclusivity, FDA approval requirements, manufacturing controls, product liability, and contractual restrictions may still affect launch timing.

Is the “trace amount” limitation important in litigation?

Yes. It can become a central claim-construction and factual issue because the claim does not state a numerical tolerance. Particle-size testing methods, sampling plans, batch records, and the meaning of “about” would likely be important in any historical infringement dispute.

References

Hoffmann-La Roche Inc. (1999). Pharmaceutical compositions containing tetrahydrolipstatin, U.S. Patent No. 6,004,996. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (1999). Xenical (orlistat) prescribing information. FDA.
U.S. Food and Drug Administration. (2007). Alli (orlistat) labeling and regulatory information. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	010704	⤷ Start Trial
Austria	200027	⤷ Start Trial
Australia	6097298	⤷ Start Trial
Australia	713192	⤷ Start Trial
Canada	2258095	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,004,996

Summary for Patent: 6,004,996